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Biomarkers are defi ned as ‘measurable characteristics 
that refl ect physiological, pharmacological, or disease 
processes’ according to the European Medicines Agency 
[1]. Th e ideal platforms for biomarker discovery include 
genomic, transcriptomic, proteomic, metabonomic and 
imaging analyses. However, most biomarkers used in 
clinical studies are based on proteomic applications as 
the majority of current drug targets are proteins, such as 
G protein-coupled receptors, ion channels, enzymes and 
components of hormone signaling pathways [2]. Further-
more, linking the results of biomarker studies using 
protein-protein interaction approaches can assist in 
systems biology approaches and could lead to hypo thesis 
generation and identifi cation of new drug targets [3].
Proteomic-based approaches for biomarker investi-
gation can be employed in diff erent aspects of medicine, 
such as elucidation of pathways aff ected in disease, 
identifi cation of individuals who are at a high risk of 
developing disease for prognosis and prediction of 
response, identifi cation of individuals who are most likely 
to respond to specifi c therapeutic interventions, and 
prediction of which patients will develop specifi c side 
eff ects (Figure 1). In line with this, biomarkers can also be 
used for patient monitoring such as testing for ‘normali-
zation’ of a biomarker signature in response to treatment 
or screening for re-appearance of a characteristic 
‘pathological’ signature. All of this equates to improve-
ment in patient care by using biomarkers in so-called 
personalized medicine approaches [4]. Th e progress and 
challenges in the translational application of proteomic 
technologies are highlighted in this new series, which 
features reviews written by leaders in the fi eld on topics 
including post-translational modifi cations and protein-
protein interactions in disease.
Currently, there are only a few molecular tests that can 
predict response to certain treatments and these are 
mainly restricted to the fi eld of oncology. Perhaps the 
best example of this is human epidermal growth factor 
receptor 2 (HER2) expression in breast cancer cells. Th is 
cell surface receptor can be blocked by the antibody-
based therapeutic HerceptinTM (trastuzumab) [5]. Such 
successes have raised hopes for discovery of biomarkers 
in other areas of medicine. However, in most cases, the 
claims for other novel biomarker candidates have not 
been proven in validation studies or in clinical trials. 
Potential reasons for this include defi ciencies in design 
and analysis, the problem that drug targets and 
biomarkers may not be causal to the disease but rather a 
result of the disease process or a co-morbid eff ect, a lack 
of congruence of preclinical models with the human 
disease, or even because of factors such as the incorrect 
enrolment of patients in clinical trials who are too 
advanced in their disease stage to show any response to 
potential therapeutics [6]. Nonetheless, a consensus has 
now been reached for testing biomarker candidates in the 
earliest stages of a disorder, as described recently for 
neurodegenerative conditions such as Alzheimer’s disease 
[7].
Th e suggestion that biomarker research has not lived 
up to the initial hype comes from the fact that publicized 
multiple ‘breakthrough’ tests have still not reached the 
market. Th is has led to skepticism from clinicians, scien-
tists and regulatory agencies, which might make the 
introduction of valid biomarkers into clinical diagnostics 
or the drug discovery industry even more diffi  cult. Th is is 
due in part to the lack of a connection between biomarker 
discovery with technologies for validation and translation 
to platforms that provide accuracy and ease of use in a 
clinical setting [8]. Apart from some biomarkers in the 
fi eld of cancer research, most have not been validated 
and have now faded from the spotlight. Major cancer 
biomarkers that have received Food and Drug Adminis-
tration (FDA) approval over the last few decades include 
prostate-specifi c antigen (PSA) for prostate cancer, 
carcinoembryonic antigen (CA)-125 for ovarian cancer 
and CA-19-9 for pancreatic cancer [9]. However, apart 
from the possible exception of PSA, most of these have 
been used mainly for monitoring treatment response and 
are not suitable for early diagnosis.© 2010 BioMed Central Ltd
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It has been suggested that the best strategy for 
biomarker qualification is through their co-development 
with drugs [10]. One of the best examples of this is the 
determination of the HER2 subtype of the epidermal 
growth factor receptor, combined with use of 
HerceptinTM, as described above. In this case, patients 
who have high levels of HER2 are more likely to respond 
to HerceptinTM treatment [5]. Thus, the use of scienti fi-
cally and analytically validated biomarkers and rationally 
designed hypothesis-testing may lead to a paradigm shift 
in drug discovery and clinical trials. Researchers are now 
required to show that biomarkers are validated before 
they can be used in regulatory decision-making. Accord-
ing to the FDA, there are now three types of biomarkers 
based on proof of concept, validity and reproducibility 
(Table  1). The last category, which requires accurate 
replication of the findings, is where most promising 
biomarker candidates have fallen short. Currently, only 
long-standing and well-established tests have been used 
for regulatory decision-making, such as fasting glucose 
tolerance or glucose clamping to monitor insulin sensi-
tivity [11].
It is clear that there is still a long way to go before the 
potential of proteomics can be entirely utilized in the 
preclinical and clinical fields, slowly progressing from 
bench to bedside and back again in an ongoing endeavor 
to improve patient outcomes. The tight regulations and 
concerted efforts outlined above will be essential in this 
journey. However, there is now optimism that further 
technological developments and interdisciplinary 
approaches will continue to advance the field of 
biomarkers so that its impact on modern medicine can 
be fully realized.
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Figure 1. Ongoing and anticipated implementations of 
proteomic-based biomarkers in various aspects of medicine.
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Table 1. Three types of biomarkers for use in clinical 
studies
Biomarker type Requirement
Exploratory biomarkers Evidence for scientific proof of concept
Probable valid biomarkers Measurement in an established analytical test  
 system and evidence explaining the clinical  
 significance of the results
Known valid biomarkers Biomarker test results should be accurately  
 replicated at different sites, laboratories or  
 agencies in cross-validation experiments
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